This translocation involves the fusion of the SYT gene at 18q11 to either homologous genes SSX1 or SSX2 at Xp11.[6, 9, 14, 25, 30, 33] This allows for several histopathological variants, including monophasic, biphasic and poorly differentiated forms.[6, 14, 33] Although there is no significant correlation among tumor location, metastases at time of diagnosis, age, sex, or the type of transcript, in patients with localized tumors, SYT-SSX2 fusion transcripts seem to predict significantly longer metastasis-free survival than SYT-SSX1 fusion transcripts.[14]. The gene discussed is SSX1; the disease is neoplasm.